Impact of drug therapy and surgery on quality of life in Crohn's disease: a systematic review (Q38430984)

3 September 2017

1 reference

title

Impact of drug therapy and surgery on quality of life in Crohn's disease: a systematic review (English)

1 reference

3 September 2017

1 reference

1 reference

2

Michael A Kamm

1 reference

3 September 2017

Emily K Wright

1

1 reference

3 September 2017

1 May 2015

1 reference

Inflammatory Bowel Diseases

3 September 2017

1 reference

3 September 2017

21

1 reference

3 September 2017

1187-1194

1 reference

3 September 2017

5

1 reference

Disability in inflammatory bowel diseases: developing ICF Core Sets for patients with inflammatory bowel diseases based on the International Classification of Functioning, Disability, and Health

3 September 2017

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000271

Long-term complications, extraintestinal manifestations, and mortality in adult Crohn's disease in population-based cohorts

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000271

Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000271

Development and validation of a patient-reported disability measurement tool for patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000271

Impact of pain on health-related quality of life in patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000271

Results of a national survey on quality of life in inflammatory bowel diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000271

Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000271

Quality of life for patients with exacerbation in inflammatory bowel disease and how they cope with disease activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000271

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000271

Mucosal healing restores normal health and quality of life in patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000271

Remission on thiopurinic immunomodulators normalizes quality of life and psychological status in patients with Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000271

The impact of biologics on health-related quality of life in patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000271

The effects of thiopurine therapy on health-related quality of life in Inflammatory Bowel Disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000271

Adalimumab improves patient-reported outcomes and reduces indirect costs in patients with moderate to severe Crohn's disease: results from the CARE trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000271

Efficacy and safety of adalimumab in Canadian patients with moderate to severe Crohn's disease: results of the Adalimumab in Canadian SubjeCts with ModErate to Severe Crohn's DiseaSe (ACCESS) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000271

Effect of surgery on health-related quality of life in patients with inflammatory bowel disease: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000271

National trends and outcomes for the surgical therapy of ileocolonic Crohn's disease: a population-based analysis of laparoscopic vs. open approaches.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000271

Quality of Life Improves Within 30 Days of Surgery for Crohn’s Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000271

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000271

The long-term benefit of surgery on health-related quality of life in patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000271

Assessment of long-term quality of life after laparoscopic and open surgery for Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000271

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000271

Patients with Crohn's disease experience reduced general health and vitality in the chronic stage: ten-year results from the IBSEN study

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000271

Long-term prognosis in Crohn's disease: factors that affect quality of life.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000271

Unfavourable outcome for women in a study of health-related quality of life, social factors and work disability in Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000271

Prognosis in Crohn's disease--based on results from a regional patient group from the county of Copenhagen

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000271

Unemployment and disability in patients with moderately to severely active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000271

Restoration of quality of life of patients with inflammatory bowel disease after one year with antiTNFα treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000271

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000271

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000271

Quality of life in patients with established inflammatory bowel disease: a UK general practice survey.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000271

The influence of personality factors on health-related quality of life of patients with inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000271

Impact of smoking on disease phenotype and postoperative outcomes for Crohn's disease patients undergoing surgery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000271

Physical activity, stress, disease activity, and quality of life in adults with Crohn disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000271

Assessing health-related quality of life in patients with inflammatory bowel disease in Zhejiang, China

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000271

Fatigue and health-related quality of life in inflammatory bowel disease: results from a population-based study in the Netherlands: the IBD-South Limburg cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000271

The relationship of inflammatory bowel disease type and activity to psychological functioning and quality of life.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000271

Determinants of life satisfaction in inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000271

The quality of life in patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000271

The quality of life in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000271

Prospective assessment of the effect on quality of life of anti-tumour necrosis factor therapy for perineal Crohn's fistulas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000271

Functional gastrointestinal disorders and mood disorders in patients with inactive inflammatory bowel disease: prevalence and impact on health.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000271

The Manitoba IBD cohort study: a population-based study of the prevalence of lifetime and 12-month anxiety and mood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000271

Alexithymia: a relevant psychological variable in near-fatal asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000271

A longitudinal study of alexithymia and psychological distress in inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000271

Inflammatory bowel disease in women: impact on relationship and sexual health

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000271

Smoking in Crohn's disease: effect on localisation and clinical course

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000271

Intestinal surgery for Crohn's disease: predictors of recovery, quality of life, and costs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000271

Gastrointestinal and psychological mediators of health-related quality of life in IBS and IBD: a structural equation modeling analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000271

Psychological disorder and severity of inflammatory bowel disease predict health-related quality of life in ulcerative colitis and Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000271

Faecal incontinence in inflammatory bowel disease: associations and effect on quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000271

Relevance of the phenotypic characteristics of Crohn's disease in patient perception of health-related quality of life.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000271

Prospective assessment of Cleveland Global Quality of Life (CGQL) as a novel marker of quality of life and disease activity in Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000271

Self-reported depressive symptoms and suicidal feelings in perianal Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000271

Personality profile and affective state of patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000271

A prospective population-based study of triggers of symptomatic flares in IBD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000271

Impact of depressive mood on relapse in patients with inflammatory bowel disease: a prospective 18-month follow-up study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000271

The social toll of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000271

INSPIRE study: does stress management improve the course of inflammatory bowel disease and disease-specific quality of life in distressed patients with ulcerative colitis or Crohn's disease? A randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000271

Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000271

Efficacy and tolerability of oral budesonide in Japanese patients with active Crohn's disease: a multicentre, double-blind, randomized, parallel-group Phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000271

Quality of life rapidly improves with budesonide therapy for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000271

A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000271

A controlled double blind study of azathioprine in the management of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000271

Course of disease, drug treatment and health-related quality of life in patients with inflammatory bowel disease 5 years after initial diagnosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000271

Clinically meaningful improvement in health-related quality of life in a randomized controlled trial of certolizumab pegol maintenance therapy for Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000271

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000271

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000271

Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000271

Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000271

Natalizumab for active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000271

A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000271

Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000271

Vedolizumab as induction and maintenance therapy for Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000271

European evidence based consensus on the diagnosis and management of Crohn's disease: special situations

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000271

The early and late results of surgical treatment for Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000271

Finnish patients with inflammatory bowel disease have fewer symptoms and are more satisfied with their treatment than patients in the previous European survey.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000271

Impact of demographic factors, medication and symptoms on disease-specific quality of life in inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000271

Coping behavior and social support contribute independently to quality of life after surgery for inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000271

Body image as a predictor of psychopathology in surgical patients with colorectal disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000271

Personality rather than clinical variables determines quality of life after major colorectal surgery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000271

Laparoscopic ileocolic resection versus infliximab treatment of distal ileitis in Crohn's disease: a randomized multicenter trial (LIR!C-trial).

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000271

Therapy of Metronidazole With Azathioprine to Prevent Postoperative Recurrence of Crohn's Disease: A Controlled Randomized Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000271

Infliximab, azathioprine, or combination therapy for Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000271

Methotrexate for the Treatment of Crohn's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000271

10.1097/MIB.0000000000000271

21 January 2018

Identifiers

DOI

1 reference

3 September 2017

1 reference

PubMed ID

25895008